Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy

Journal article

Drug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple sources, and the use of such integrated databases to develop statistical models can inform protocol development and reduce the risks in developing new therapies. Achieving regulatory endorsement of such models through defined pathways at the US Food and Drug Administration and European Medicines Authority allows such tools to be used by the drug development community for defined contexts of use without further need for discussion of the underlying model(s). The Duchenne Regulatory Science Consortium (D-RSC) has brought together multiple stakeholders to develop a clinical trial simulation tool for Duchenne muscular dystrophy using such an approach. Here we describe the work of D-RSC as an example of how such an approach may be effective at reducing uncertainty in drug development for rare diseases, and thus bringing effective therapies to patients faster.

Authors: Conrado, DJ; Larkindale, J; Berg, A; Hill, M; Burton, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Journal of Pharmacokinetics and Pharmacodynamics
• Volume: 46
• Issue: 5
• Pages: 441-455
• Publication date: 2019-05-24
• Acceptance date: 2019-05-15
• DOI: 10.1007/s10928-019-09642-7
• EISSN: 1573-8744
• ISSN: 1567-567X
• Pmid: 31127458
• Language: English
• Keywords: Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC); FFR